Welcome to LookChem.com Sign In|Join Free

CAS

  • or
4-CHLORO-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDINE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

479633-63-1

Post Buying Request

479633-63-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

479633-63-1 Usage

Uses

4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine is a reagent in the synthesis of (+)-tofacitinib, a selective Janus kinase 3 inhibitor (JAK3) and an immunosuppressant drug.

Check Digit Verification of cas no

The CAS Registry Mumber 479633-63-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,9,6,3 and 3 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 479633-63:
(8*4)+(7*7)+(6*9)+(5*6)+(4*3)+(3*3)+(2*6)+(1*3)=201
201 % 10 = 1
So 479633-63-1 is a valid CAS Registry Number.
InChI:InChI=1/C13H10ClN3O2S/c1-9-2-4-10(5-3-9)20(18,19)17-7-6-11-12(14)15-8-16-13(11)17/h2-8H,1H3

479633-63-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (ADE000077)  4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine  AldrichCPR

  • 479633-63-1

  • ADE000077-1G

  • 7,411.95CNY

  • Detail

479633-63-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine

1.2 Other means of identification

Product number -
Other names 4-Chloro-7-(p-toluenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:479633-63-1 SDS

479633-63-1Relevant articles and documents

Identification of N-Phenyl-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis

Zhu, Yuqin,Ma, Yuxiang,Zu, Weidong,Song, Jianing,Wang, Hua,Zhong, You,Li, Hongmei,Zhang, Yanmin,Gao, Qianqian,Kong, Bo,Xu, Junyu,Jiang, Fei,Wang, Xinren,Li, Shuwen,Liu, Chenhe,Liu, Haichun,Lu, Tao,Chen, Yadong

, p. 6748 - 6773 (2020)

A series of N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives with NF-κB inducing kinase (NIK) inhibitory activity were obtained through structure-based drug design and synthetic chemistry. Among them, 4-(3-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (12f) was identified as a highly potent NIK inhibitor, along with satisfactory selectivity. The pharmacokinetics of 12f and its ability to inhibit interleukin 6 secretion in BEAS-2B cells were better than compound 1 developed by Amgen. Oral administration of different doses of 12f in an imiquimod-induced psoriasis mouse model showed effective alleviation of psoriasis, including invasive erythema, swelling, skin thickening, and scales. The underlying pathological mechanism involved attenuation of proinflammatory cytokine and chemokine gene expression, and the infiltration of macrophages after the treatment of 12f. This work provides a foundation for the development of NIK inhibitors, highlighting the potential of developing NIK inhibitors as a new strategy for the treatment of psoriasis.

PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR

-

, (2022/03/02)

The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.

PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR

-

, (2022/03/04)

The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.

Preparation method of key intermediate of JAK inhibitor

-

Paragraph 0043-0045; 0050-0052; 0057-0059, (2021/09/04)

The invention discloses a preparation method of a key intermediate of a JAK inhibitor. The preparation method comprises the following steps: step a, protecting an amino group of a raw material 4-chloro-7H-pyrrole-[2.3-d]-pyrimidine to synthesize 4-chloro-

Selective JAK1 inhibitor compound as well as preparation method and application thereof

-

Paragraph 0069-0074, (2021/01/30)

The invention provides a heterocyclic compound serving as a JAK1 inhibitor and synthesis and use methods, and particularly provides a compound shown as a formula (I), a preparation method of the compound and application of the compound serving as a JAK1 i

COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT

-

Paragraph 0074, (2021/05/13)

The present invention relates to a compound having TrkA inhibitory activity and a pharmaceutical composition for preventing or treating pain containing the same as an active ingredient. The compound provided in one aspect of the present invention has excellent TrkA inhibitory activity and exhibits excellent pain inhibitory effects in an animal model of pain after a surgery, and thus can be effectively used as an analgesic.

PROCESS FOR PREPARATION OF ABROCITINIB

-

Paragraph 0107, (2021/01/23)

The present invention relates to crystalline abrocitinib characterized by X-ray powder diffraction (XRPD) spectrum having peak reflections at about 12.9, 14.7, 19.4, 23.2 and 25.2 ±0.2 degrees 2 theta, and process for its preparation. The present invention relates to amorphous solid dispersion comprising abrocitinib or salt thereof together with at least one pharmaceutically acceptable carrier and process for its preparation.

TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF

-

Paragraph 00199; 00288, (2020/05/28)

Provided are novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e. g., inflammatory diseases, immune-mediated diseases or cancer).

A class of pyrrolopyrimidine derivatives, and synthesis method thereof

-

Paragraph 0070-0073, (2020/05/29)

The invention discloses a class of pyrrolopyrimidine derivatives, wherein the pyrrolopyrimidine derivative has a structural general formula represented by a formula (I). The invention also discloses asynthesis method of the compound represented by the for

PROCESS FOR PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

-

Page/Page column 10, (2020/09/27)

The present invention relates to an improved process for preparation of tofacitinib (I) and pharmaceutically acceptable salt thereof. (I)

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 479633-63-1